Clinical trials
Localized Breast Carcinoma clinical trials
Below are recruiting localized breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 258 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT05600127RecruitingPhase 2
Chemotherapy then immunotherapy plus surgery for advanced bladder cancer
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT06738966RecruitingPhase 1
BL0175 for advanced HR-positive breast or gynecologic cancer
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
Changchun, JilinAges 18 years+ - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07622797RecruitingPhase 2
Immunotherapy with chemotherapy and radiation for esophageal cancer
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Luoyang, HenanAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Scottsdale, ArizonaAges 18 years+ - NCT05973864RecruitingPhase 2
Capecitabine plus pembrolizumab after TNBC surgery and chemo
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
AmiensAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06598761Recruiting
Immunotherapy plus radiation after surgery for advanced UTUC
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
BeijingAges 18–80 - NCT07455032RecruitingPhase 1
Neoadjuvant therapy combo for head and neck cancer
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT07293468RecruitingPhase 2/Phase 3
Comparing two treatments for advanced liver cancer
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hong KongAges 18–80 - NCT07012031RecruitingPhase 1/Phase 2
Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer
This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06959108RecruitingPhase 2
Comparing two treatments for head and neck cancer before chemoradiation
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
VillejuifAges 18–75 - NCT05010109Recruiting
Testing heart safety and fitness during lung cancer chemoradiation
This study looks at how lung cancer treatment affects the heart and whether a “walking test” and blood tests can track heart fitness and injury. It may help by improving how cancer therapy is planned and monitored for heart safety.
Houston, TexasAges 18 years+ - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+
Hear when a new Localized Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for localized breast carcinoma?
- Yes. Clin2 currently lists 258 recruiting localized breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a localized breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a localized breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.